US ships Marburg vaccines to Rwanda after 11 die in outbreak
By Philbert Girinema and Chandni Shah
KIGALI, Oct 5 (Reuters) -The United States government completed an initial shipment of vaccine doses and therapeutic drugs for Marburg disease to Rwanda on Oct. 4, Thierry Roels, U.S. CDC Country Director in Rwanda told Reuters on Saturday.
The U.S. government is also working closely with international partners and Rwanda's ministry of health on the start of clinical trials to evaluate investigational countermeasures, he said.
Roels added that the U.S. government was considering additional shipments that can supply the clinical trials, but did not say how many doses had been delivered on Friday.
Rwanda's first outbreak of the viral hemorrhagic fever was detected in late September, with 36 cases and 11 deaths reported so far. Marburg has a fatality rate as high as 88%.
Rwandan Health Minister Sabin Nsanziman said on Thursday that the country will start clinical trials of experimental vaccines and treatments for the disease.
Four vaccine candidates have been evaluated for potential use in trials by WHO, but only one, made by the Sabin Vaccine Institute non-profit, has data from early-stage human trials showing it is safe and led to an immune response. Further testing of the vaccines outside of outbreak settings is not possible because of the risks involved.
The Sabin Vaccine Institute said on Saturday it had delivered around 700 doses of its vaccine to Rwanda, to be used in a trial targeting frontline workers, including healthcare professionals.
The non-profit institute also said it plans to supply additional vaccines pending a request from the Rwanda government and authorization from U.S. Center for the Biomedical Advanced Research and Development Authority (BARDA).
Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in response to the outbreak.
Marburg symptoms include high fever, severe headaches and malaise within seven days of infection and later severe nausea, vomiting, and diarrhea. It is transmitted to humans by fruit bats, and then spreads through contact with the bodily fluids of those infected.
Reporting by Philbert Girinema in Kigali and Chandni Shah in Bengaluru; Additional reporting by Elias Biryabarema in Nairobi; Editing by Sandra Maler
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
